摘要
乳腺癌患者发生脑转移后,由于血脑屏障的存在,药物难以到达脑部发挥药效,其治疗手段有限,目前以放疗和手术治疗为主,预后较差。抗体药物偶联类(antibody-drug conjugate,ADC)药物通过其独特的靶向递送机制,提高了药物在脑内的浓度和疗效,使其在乳腺癌脑转移方面具有卓越的疗效。本文重点对以HER-2、TROP2为靶点的ADC药物在乳腺癌脑转移治疗中的研究进展进行综述。我们期待后续更优秀的ADC药物设计方案和优化使用方案(包括联合其他药物、放疗等),能使乳腺癌脑转移患者获得更长的生存期、更好的生活质量。
The existence of blood-brain barrier makes it difficult for the drugs to act on the brain lesion of patients with breast cancer brain metastasis(BCBM).As radiotherapy and surgery are the main clinical treatments for BCBM,its prognosis is very poor.The unique targeted delivery mechanism makes antibody-drug conjugate(ADC)drugs have a better concentration and efficacy in the brain.This paper intends to give a review of the research progress of ADC drugs targeting HER-2 and TROP2 in the treatment of BCBM,believing that more and more excellent ADC drug design and optimal use(including combination with other drugs,radiotherapy,etc.)will enable BCBM patients obtain longer survival time and better quality of life.
作者
温鑫鑫
李南林
WEN Xinxin;LI Nanlin(Department of Thyroid Breast and Vascular Surgery,the First Affiliated Hospital of Air Force Medical University,Xi'an,Shaanxi 710032,China)
出处
《中华神经外科疾病研究杂志》
CAS
2024年第5期72-75,共4页
Chinese Journal of Neurosurgical Disease Research
基金
中国抗癌协会HER2靶点中国科研基金(课题编号:CORP-239-N13)。
关键词
乳腺癌
脑转移
抗体药物偶联类药物
血脑屏障
Breast cancer
Brain metastasis
Antibody-drug conjugate drugs
Blood-brain barrier
